ReviewPharmaceutical research2008
RNAi for treating hepatitis B viral infection.
Review in Pharmaceutical research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed.
- Process Optimization of Novel Boronophenylalanine Liposomes Through Box-Behnken Response Surface Design and Preliminary Evaluation in A549 Lung Carcinoma Cells for Boron Neutron Capture Therapy.Molecules (Basel, Switzerland) · 2026Article
- Small nucleic acid drugs-the dawn of functional cure of chronic hepatitis B.Frontiers in pharmacology · 2025Review
- Review
- Combining RNA Interference and RIG-I Activation to Inhibit Hepatitis E Virus Replication.Viruses · 2024Article
- The effect of modification of DNA interference on myostatin gene expression in mice.Journal of genetics · 2024Article
- The role of noncoding RNAs in the tumor microenvironment of hepatocellular carcinoma.Acta biochimica et biophysica Sinica · 2023Review
- Transplantation of IL-1β siRNA-modified bone marrow mesenchymal stem cells ameliorates type II collagen-induced rheumatoid arthritis in rats.Experimental and therapeutic medicine · 2022Article
- Inhibition of SARS-CoV-2 Replication by a Small Interfering RNA Targeting the Leader Sequence.Viruses · 2021Article
- An in silico analysis of effective siRNAs against COVID-19 by targeting the leader sequence of SARS-CoV-2.Advances in cell and gene therapy · 2021Article
- Correlation of serum microRNA-122 level with the levels of Alanine aminotransferase and HBV-DNA in Chronic HBV-infected patients.Medical journal of the Islamic Republic of Iran · 2021Article
- Computational prediction of potential siRNA and human miRNA sequences to silence orf1ab associated genes for future therapeutics against SARS-CoV-2.Informatics in medicine unlocked · 2021Article
- Prevention of HBV Recurrence after Liver Transplant: A Review.Journal of clinical and translational hepatology · 2020Review
- Review
- Stimulated phospholipid synthesis is key for hepatitis B virus replications.Scientific reports · 2019Article
- A Global View to HBV Chronic Infection: Evolving Strategies for Diagnosis, Treatment and Prevention in Immunocompetent Individuals.International journal of environmental research and public health · 2019Review
- Application of Locked Nucleic Acid Oligonucleotides for siRNA Preclinical Bioanalytics.Scientific reports · 2019Article
- Review
- Are RNA Viruses Candidate Agents for the Next Global Pandemic? A Review.ILAR journal · 2017Review
- Drugs in Development for Hepatitis B.Drugs · 2017Review
- Treatment of hepatitis B virus: an update.Future microbiology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Chronic hepatitis B virus (HBV) infection is one of the leading causes of liver cirrhosis and hepatocellular carcinoma (HCC). Current treatment strategies of HBV infection including the use of interferon (IFN)-alpha and nucleotide analogues such as lamivudine and adefovir have met with only partial success. Therefore, it is necessary to develop more effective antiviral therapies that can clear HBV infection with fewer side effects. RNA interference (RNAi), by which a small interfering RNA (siRNA) induces the gene silence at a post-transcriptional level, has the potential of treating HBV infection. The successful use of chemically synthesized siRNA, endogenous expression of small hairpin RNA (shRNA) or microRNA (miRNA) to silence the target gene make this technology towards a potentially rational therapeutics for HBV infection. However, several challenges including poor siRNA stability, inefficient cellular uptake, widespread biodistribution and non-specific effects need to be overcome. In this review, we discuss several strategies for improving the anti-HBV therapeutic efficacy of siRNAs, while avoiding their off-target effects and immunostimulation. There is an in-depth discussion on the (1) mechanisms of RNAi, (2) methods for siRNA/shRNA production, (3) barriers to RNAi-based therapies, and (4) delivery strategies of siRNA for treating HBV infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.